Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: Results from the LIPID study

International Journal of Obesity

Volumn 33, Issue 1, 2009, Pages 123-130

  Soderberg S ^a,f   Colquhoun, D ^b   Keech, A ^c   Yallop, J ^d   Barnes, E H ^c   Pollicino, C ^c   Simes, J ^c   Tonkin, A M ^d   Nestel, P ^e  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adiponectin; Atherosclerosis; Cardiovascular disease; Leptin; Pravastatin; Risk prediction

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; LEPTIN; NITRATE; ORAL ANTIDIABETIC AGENT; PLACEBO; PRAVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EXPLANATORY VARIABLE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; PLASMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR;

ADIPONECTIN; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEPTIN; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PRAVASTATIN; RECURRENCE; RISK; STROKE;

EID: 58149484949     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2008.224     Document Type: Article

References (43)

1. Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002; 26: 1407-1433.
2. Ahima RS. Central actions of adipocyte hormones. Trends Endocrinol Metab 2005; 16: 307-313.
3. Cooke JP, Oka RK. Does leptin cause vascular disease? Circulation 2002; 106: 1904-1905.
4. Correia ML, Haynes WG. Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens 2004; 13: 215-223.
5. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533-1540.
6. O'Rourke L, Gronning LM, Yeaman SJ, Shepherd PR. Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J Biol Chem 2002; 277: 42557-42562.
7. Zeidan A, Purdham DM, Rajapurohitam V, Javadov S, Chakrabarti S, Karmazyn M. Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II- and endothelin-1-dependent mechanisms and mediates stretch-induced hypertrophy. J Pharmacol Exp Ther 2005; 315: 1075-1084.
8. Söderberg S, Ahrén B, Jansson JH, Johnson O, Hallmans G, Asplund K et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999; 246: 409-418.
9. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-3056.
10. Swarbrick MM, Havel PJ. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 2008; 6: 87-102.
11. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-228.
12. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003; 14: 561-566.
13. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
14. Lindsay RS, Resnick HE, Zhu J, Tun ML, Howard BV, Zhang Y et al. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2005; 25: e15-e16.
15. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
16. Marschner IC, Colquhoun D, Simes RJ, Glasziou P, Harris P, Singh BB et al. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators. J Am Coll Cardiol 2001; 38: 56-63.
17. Wallerstedt SM, Eriksson AL, Niklason A, Ohlsson C, Hedner T. Serum leptin and myocardial infarction in hypertension. Blood Press 2004; 13: 243-246.
18. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 2004; 44: 1819-1824.
19. Piatti P, Di Mario C, Monti LD, Fragasso G, Sgura F, Caumo A et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 2003; 108: 2074-2081.
20. Söderberg S, Stegmayr B, Stenlund H, Sjöström LG, Ågren A, Johansson L et al. Leptin, but not adiponectin, predicts stroke in males. J Intern Med 2004; 256: 128-136.
21. Söderberg S, Stegmayr B, Ahlbeck-Glader C, Slunga-Birgander L, Ahrén B, Olsson T. High leptin levels are associated with stroke. Cerebrovasc Dis 2003; 15: 63-69.
22. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47-60.
23. Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation 2008; 117: 3238-3249.
24. Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gomez-Reino JJ et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 2005; 579: 295-301.
25. Ahima RS, Osei SY. Leptin signaling. Physiol Behav 2004; 81: 223-241.
26. Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestel PJ. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab 2005; 90: 5998-6005.
27. Fain JN, Kanu A, Bahouth SW, Cowan GS, Lloyd Hiler M. Inhibition of leptin release by atrial natriuretic peptide (ANP) in human adipocytes. Biochem Pharmacol 2003; 65: 1883-1888.
28. Beltowski J, Jamroz-Wisniewska A, Borkowska E, Wojcicka G. Up-regulation of renal Na+, K+-ATPase: the possible novel mechanism of leptin-induced hypertension. Pol J Pharmacol 2004; 56: 213-222.
29. La Cava A, Alviggi C, Matarese G. Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med 2004; 82: 4-11.
30. Shamsuzzaman AS, Winnicki M, Wolk R, Svatikova A, Phillips BG, Davison DE et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 2004; 109: 2181-2185.
31. Hukshorn CJ, van Dielen FM, Buurman WA, Westerterp-Plantenga MS, Campfield LA, Saris WH. The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects. Int J Obes Relat Metab Disord 2002; 26: 504-509.
32. Canavan B, Salem RO, Schurgin S, Koutkia P, Lipinska I, Laposata M et al. Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. J Clin Endocrinol Metab 2005; 90: 5779-5785.
33. Venugopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005; 14: 33-37.
34. Maingrette F, Renier G. Leptin increases lipoprotein lipase secretion by macrophages: involvement of oxidative stress and protein kinase C. Diabetes 2003; 52: 2121-2128.
35. Lundasen T, Liao W, Angelin B, Rudling M. Leptin induces the hepatic high density lipoprotein receptor scavenger receptor B type I (SR-BI) but not cholesterol 7alpha-hydroxylase (Cyp7a1) in leptin-deficient (ob/ob) mice. J Biol Chem 2003; 278: 43224-43228.
36. Zhao SP, Wu ZH. Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits. Clin Chim Acta 2005; 360: 133-140.
37. Takahashi-Yasuno A, Masuzaki H, Miyawaki T, Ogawa Y, Matsuoka N, Hayashi T et al. Leptin receptor polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by simvastatin in Japanese men. Diabetes Res Clin Pract 2003; 62: 169-175.
38. Raclot T, Groscolas R, Langin D, Ferre P. Site-specific regulation of gene expression by n-3 polyunsaturated fatty acids in rat white adipose tissues. J Lipid Res 1997; 38: 1963-1972.
39. Flier JS. Clinical review 94: what's in a name? In search of leptin's physiologic role. J Clin Endocrinol Metab 1998; 83: 1407-1413.
40. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89.
41. Efstathiou SP, Tsioulos DI, Tsiakou AG, Gratsias YE, Pefanis AV, Mountokalakis TD. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 2005; 36: 1915-1919.
42. Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007; 167: 1510-1517.
43. Sattar N, Nelson SM. Adiponectin, diabetes, and coronary heart disease in older persons: unraveling the paradox. J Clin Endocrinol Metab 2008; 93: 3299-3301.